Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in polymyositis or dermatomyositis (proof-of-concept)
2012-005772-34Phase 2Terminated
- Sponsor
- Servier
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gevokizumab in polymyositis (PM), dermatomyositis (DM), sponsored by Servier. Started May 2013; status: terminated.
02
Drugs
gevokizumab
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on 2012-005772-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005772-34.